文献速递血栓与止血

小鼠活化凝血因子VII中一个氨基酸决定其内皮蛋白C受体(EPCR)结合并调节其EPCR依赖性体内止血活性

One amino acid in mouse activated factor VII defines its endothelial protein C receptor (EPCR) binding and modulates its EPCR-dependent hemostatic activity in vivo.
PubMed 文献 · J Thromb Haemost · 2017-02-14

本研究探讨小鼠活化凝血因子VII(mFVIIa)与内皮蛋白C受体(EPCR)的相互作用。通过单氨基酸替换发现,mFVIIa或小鼠蛋白C第4位Phe是结合mEPCR的关键;在血友病小鼠中,含Phe4的mFVIIa较mFVIIa止血能力增加1.9-2.5倍且依赖EPCR结合,重现了三突变体mFVIIa-FMR的观察结果。

要点

  • mFVIIa或mPC第4位Phe是与mEPCR相互作用的关键。
  • 血友病小鼠中,含Phe4的mFVIIa较mFVIIa止血能力增加1.9-2.5倍,且依赖EPCR结合。
  • 小鼠与人类FVIIa-EPCR结合存在序列差异,Leu8对人类结合关键。

核心结论

  • mFVIIa或mPC第4位Phe是mEPCR结合的关键,含Phe4的mFVIIa在血友病小鼠中表现出EPCR结合依赖的增强止血功能。

研究设计与样本

  • 研究对mFVIIa或mPC第4、8或9位单氨基酸变体的mEPCR结合特性进行体外研究,并在血友病小鼠中评估体内止血能力。

主要发现

  • mFVIIa或mPC第4位Phe是mEPCR结合的唯一关键位点。
  • 血友病小鼠中,给予含Phe4的mFVIIa后止血能力较mFVIIa增加1.9-2.5倍,且该增强依赖EPCR结合。

临床怎么用

  • 作者认为,调节EPCR-FVIIa相互作用可能带来改进的FVIIa治疗药物。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: Essentials The lack of factor (F) VIIa-endothelial protein C receptor (EPCR) binding in mice is unresolved. A single substitution of Leu4 to Phe in mouse FVIIa (mFVIIa) enables its interaction with EPCR. mFVIIa with a Phe4 shows EPCR binding-dependent enhanced hemostatic function in vivo vs. mFVIIa. Defining the FVIIa-EPCR interaction in mice allows for further investigating its biology in vivo. SUMMARY: Background Human activated factor VII (hFVIIa), which is used in hemophilia treatment, binds to the endothelial protein C (PC) receptor (EPCR) with unclear hemostatic consequences. Interestingly, mice lack the activated FVII (FVIIa)-EPCR interaction. Therefore, to investigate the hemostatic consequences of this interaction in hemophilia, we previously engineered a mouse FVIIa (mFVIIa) molecule that bound mouse EPCR (mEPCR) by using three substitutions from mouse PC (mPC), i.e. Leu4→Phe, Leu8→Met, and Trp9→Arg. The resulting molecule, mFVIIa-FMR, modeled the EPCR-binding properties of hFVIIa and showed enhanced hemostatic capacity in hemophilic mice versus mFVIIa. These data implied a role of EPCR in the action of hFVIIa in hemophilia treatment. However, the substitutions in mFVIIa-FMR only broadly defined the sequence determinants for its mEPCR interaction and enhanced function in vivo. Objectives To determine the individual contributions of mPC Phe4, Met8 and Arg9 to the in vitro/in vivo properties of mFVIIa-FMR. Methods The mEPCR-binding properties of single amino acid variants of mFVIIa or mPC at position 4, 8 or 9 were investigated. Results and conclusions Phe4 in mFVIIa or mPC was solely critical for interaction with mEPCR. In hemophilic mice, administration of mFVIIa harboring a Phe4 resulted in a 1.9-2.5-fold increased hemostatic capacity versus mFVIIa that was EPCR binding-dependent. This recapitulated previous observations made with triple-mutant mFVIIa-FMR. As Leu8 is crucial for hFVIIa-EPCR binding, we describe the sequence divergence of this interaction in mice, now allowing its further characterization in vivo. We also illustrate that modulation of the EPCR-FVIIa interaction may lead to improved FVIIa therapeutics.

来源:J Thromb Haemost,查看原文。版权归原作者所有。

引用

  1. Pavani G, Zintner SM, Ivanciu L, et al. One amino acid in mouse activated factor VII defines its endothelial protein C receptor (EPCR) binding and modulates its EPCR-dependent hemostatic activity in vivo. J Thromb Haemost. 2017. PMID: 28035745. doi:10.1111/jth.13607

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。